# Viridian Therapeutics, Inc.\\DE: financial statements, quarterly

VRDN · Nasdaq · CIK 1590750 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vrdn.md) · [Financials](/companies/vrdn/financials.md) · [Filings](/companies/vrdn/filings.md) · [Insiders](/companies/vrdn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vrdn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001590750-24-000023.md) | [0.1 d](/filings/0001590750-26-000007.md) | [0.1](/filings/0001590750-25-000008.md) | [0.1](/filings/0001590750-25-000012.md) | [0.1](/filings/0001590750-25-000020.md) | [0.1 d](/filings/0001590750-26-000007.md) | [0.1](/filings/0001590750-26-000012.md) | [0.1](/filings/0001590750-26-000018.md) | [70.6](/filings/0001590750-25-000020.md) | [0.1 d](/filings/0001590750-26-000007.md) | [0.1](/filings/0001590750-26-000012.md) | [0.3](/filings/0001590750-26-000018.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | [17.1](/filings/0001590750-26-000012.md) | [20.2](/filings/0001590750-26-000018.md) | not reported | not reported | [38.7](/filings/0001590750-26-000012.md) | [55.0](/filings/0001590750-26-000018.md) |
| Operating income | $m | [(51.2)](/filings/0001590750-24-000023.md) | [(71.5) d](/filings/0001590750-26-000007.md) | [(55.9)](/filings/0001590750-25-000008.md) | [(72.2)](/filings/0001590750-25-000012.md) | [(83.5)](/filings/0001590750-25-000020.md) | [(87.5) d](/filings/0001590750-26-000007.md) | [(93.9)](/filings/0001590750-26-000012.md) | [(107)](/filings/0001590750-26-000018.md) | [(40.0)](/filings/0001590750-25-000020.md) | [(123) d](/filings/0001590750-26-000007.md) | [(116)](/filings/0001590750-26-000012.md) | [(126)](/filings/0001590750-26-000018.md) |
| Interest expense | $m | [0.6](/filings/0001590750-24-000023.md) | [0.4 d](/filings/0001590750-26-000007.md) | [0.6](/filings/0001590750-25-000008.md) | [0.6](/filings/0001590750-25-000012.md) | [0.5](/filings/0001590750-25-000020.md) | [0.5 d](/filings/0001590750-26-000007.md) | [0.6](/filings/0001590750-26-000012.md) | [0.5](/filings/0001590750-26-000018.md) | [0.6](/filings/0001590750-25-000020.md) | [3.3 d](/filings/0001590750-26-000007.md) | [3.5](/filings/0001590750-26-000012.md) | [8.3](/filings/0001590750-26-000018.md) |
| Net income | $m | [(47.7)](/filings/0001590750-24-000023.md) | [(66.9) d](/filings/0001590750-26-000007.md) | [(48.5)](/filings/0001590750-25-000020.md) | [(65.0)](/filings/0001590750-25-000020.md) | [(76.7)](/filings/0001590750-25-000020.md) | [(79.7) d](/filings/0001590750-26-000007.md) | [(86.9)](/filings/0001590750-26-000018.md) | [(101)](/filings/0001590750-26-000018.md) | [(34.6)](/filings/0001590750-25-000020.md) | [(120) d](/filings/0001590750-26-000007.md) | [(105)](/filings/0001590750-26-000018.md) | [(127)](/filings/0001590750-26-000018.md) |
| Diluted EPS | $ per share | [(1.09)](/filings/0001590750-24-000023.md) | not reported | [(0.79)](/filings/0001590750-24-000012.md) | [(1.02)](/filings/0001590750-24-000019.md) | [(1.15)](/filings/0001590750-24-000023.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(1.09)](/filings/0001590750-24-000023.md) | not reported | [(0.79)](/filings/0001590750-24-000012.md) | [(1.02)](/filings/0001590750-24-000019.md) | [(1.15)](/filings/0001590750-24-000023.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: not reported
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [324](/filings/0001590750-23-000013.md) | [486](/filings/0001590750-25-000004.md) | [627](/filings/0001590750-24-000012.md) | [582](/filings/0001590750-24-000019.md) | [767](/filings/0001590750-24-000023.md) | [738](/filings/0001590750-26-000007.md) | [657](/filings/0001590750-25-000008.md) | [579](/filings/0001590750-25-000012.md) | [572](/filings/0001590750-25-000020.md) | [894](/filings/0001590750-26-000018.md) | [785](/filings/0001590750-26-000012.md) | [1,081](/filings/0001590750-26-000018.md) |
| Total assets | $m | [329](/filings/0001590750-23-000013.md) | [490](/filings/0001590750-25-000004.md) | [630](/filings/0001590750-24-000012.md) | [586](/filings/0001590750-24-000019.md) | [772](/filings/0001590750-24-000023.md) | [742](/filings/0001590750-26-000007.md) | [661](/filings/0001590750-25-000008.md) | [582](/filings/0001590750-25-000012.md) | [577](/filings/0001590750-25-000020.md) | [899](/filings/0001590750-26-000018.md) | [789](/filings/0001590750-26-000012.md) | [1,097](/filings/0001590750-26-000018.md) |
| Current liabilities | $m | [23.2](/filings/0001590750-23-000013.md) | [26.6](/filings/0001590750-25-000004.md) | [26.1](/filings/0001590750-24-000012.md) | [36.8](/filings/0001590750-24-000019.md) | [41.4](/filings/0001590750-24-000023.md) | [47.9](/filings/0001590750-26-000007.md) | [33.7](/filings/0001590750-25-000008.md) | [52.6](/filings/0001590750-25-000012.md) | [50.7](/filings/0001590750-25-000020.md) | [70.7](/filings/0001590750-26-000018.md) | [51.8](/filings/0001590750-26-000012.md) | [63.8](/filings/0001590750-26-000018.md) |
| Total liabilities | $m | [45.2](/filings/0001590750-23-000013.md) | [48.4](/filings/0001590750-25-000004.md) | [47.9](/filings/0001590750-24-000012.md) | [56.3](/filings/0001590750-24-000019.md) | [64.4](/filings/0001590750-24-000023.md) | [70.8](/filings/0001590750-26-000007.md) | [56.5](/filings/0001590750-25-000008.md) | [67.2](/filings/0001590750-25-000012.md) | [74.2](/filings/0001590750-25-000020.md) | [177](/filings/0001590750-26-000018.md) | [153](/filings/0001590750-26-000012.md) | [435](/filings/0001590750-26-000018.md) |
| Long-term debt | $m | [20.0](/filings/0001590750-23-000013.md) | [20.2](/filings/0001590750-25-000004.md) | [20.3](/filings/0001590750-24-000012.md) | [17.5](/filings/0001590750-24-000019.md) | [20.5](/filings/0001590750-24-000023.md) | [20.6](/filings/0001590750-25-000020.md) | [20.7](/filings/0001590750-25-000008.md) | [12.4](/filings/0001590750-25-000012.md) | [20.9](/filings/0001590750-25-000020.md) | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [0.0](/filings/0001590750-24-000019.md) | not reported | [3.0](/filings/0001590750-24-000019.md) | not reported | [0.0](/filings/0001590750-25-000012.md) | not reported | [8.4](/filings/0001590750-25-000012.md) | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [284](/filings/0001590750-24-000023.md) | [442](/filings/0001590750-26-000007.md) | [583](/filings/0001590750-25-000020.md) | [529](/filings/0001590750-25-000020.md) | [707](/filings/0001590750-25-000020.md) | [672](/filings/0001590750-26-000018.md) | [604](/filings/0001590750-26-000018.md) | [515](/filings/0001590750-26-000018.md) | [503](/filings/0001590750-25-000020.md) | [722](/filings/0001590750-26-000018.md) | [636](/filings/0001590750-26-000018.md) | [662](/filings/0001590750-26-000018.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(39.0) d](/filings/0001590750-24-000023.md) | [(38.0) d](/filings/0001590750-26-000007.md) | [(45.2)](/filings/0001590750-25-000008.md) | [(46.1) d](/filings/0001590750-25-000012.md) | [(67.7) d](/filings/0001590750-25-000020.md) | [(73.3) d](/filings/0001590750-26-000007.md) | [(92.7)](/filings/0001590750-26-000012.md) | [(75.4) d](/filings/0001590750-26-000018.md) | [(84.6) d](/filings/0001590750-25-000020.md) | [(23.8) d](/filings/0001590750-26-000007.md) | [(120)](/filings/0001590750-26-000012.md) | [(105) d](/filings/0001590750-26-000018.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001590750-24-000023.md) | [0.0 d](/filings/0001590750-26-000007.md) | [0.0](/filings/0001590750-25-000008.md) | [0.1 d](/filings/0001590750-25-000012.md) | [0.3 d](/filings/0001590750-25-000020.md) | [0.1 d](/filings/0001590750-26-000007.md) | [0.1](/filings/0001590750-26-000012.md) | [0.0 d](/filings/0001590750-26-000018.md) | [0.1 d](/filings/0001590750-25-000020.md) | [0.2 d](/filings/0001590750-26-000007.md) | [0.0](/filings/0001590750-26-000012.md) | [1.3 d](/filings/0001590750-26-000018.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [11.2](/filings/0001590750-22-000012.md) | [26.1](/filings/0001590750-23-000003.md) | [27.8](/filings/0001590750-23-000008.md) | [33.7](/filings/0001590750-23-000013.md) | [42.2](/filings/0001590750-24-000012.md) | [43.3](/filings/0001590750-24-000019.md) | [43.7](/filings/0001590750-24-000023.md) | [61.1](/filings/0001590750-25-000008.md) | [63.9](/filings/0001590750-25-000012.md) | [66.4](/filings/0001590750-25-000020.md) | [81.3](/filings/0001590750-26-000012.md) | [81.6](/filings/0001590750-26-000018.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 113,292,269 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001590750-26-000018.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.